Lapozan

Olanzapine, the active ingredient in Lapozan, is a atypical antipsychotic presented as an oral tablet for oral use. It treats schizophrenia and bipolar disorder in adults.

GNH USA supplies Lapozan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapine is an atypical antipsychotic used in the management of major psychotic and mood disorders.

- Schizophrenia: reduces psychotic symptoms such as delusions, hallucinations and thought disorder. - Bipolar I disorder (manic or mixed episodes): controls acute mania and stabilises mood. - Maintenance therapy for bipolar disorder: helps prevent recurrence of manic and depressive episodes.

Olanzapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Weight gain: increased appetite and caloric intake. - Sedation: drowsiness or fatigue. - Dry mouth: reduced salivation. - Constipation: slowed gastrointestinal motility. - Dizziness: light‑headedness, especially when standing. - Increased appetite: may contribute to weight changes.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but life‑threatening reaction. - Agranulocytosis: severe drop in white blood cells. - Hyperglycemia: marked increase in blood sugar levels. - Tardive dyskinesia: involuntary movements with long‑term use. - Seizures: heightened risk in predisposed individuals. - Myocarditis: inflammation of the heart muscle.

Before initiating olanzapine therapy, clinicians should consider several safety measures.

- Metabolic monitoring: regularly assess weight, glucose and lipid levels. - Cardiovascular assessment: evaluate for existing heart disease or risk factors. - Seizure risk: use cautiously in patients with a history of seizures. - Elderly patients: avoid use in dementia‑related psychosis due to increased mortality. - Discontinuation: taper gradually to minimise withdrawal or relapse. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Olanzapine can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP1A2 inhibitors (e.g., fluvoxamine): may increase olanzapine levels. - Other antipsychotics: additive central nervous system effects. - CNS depressants (alcohol, benzodiazepines): heightened sedation and respiratory depression.

Moderate Interactions (Monitor Closely):\n- CYP1A2 inducers (e.g., smoking, carbamazepine): may reduce efficacy. - Lithium: increased risk of neurotoxicity. - QT‑prolonging agents: potential for cardiac rhythm disturbances.